MDRNA (NASDAQ: [[ticker:MRNA]]), a Bothell, WA-based biotech company, said today it received tentative FDA approval of a generic version of calcitonin nasal spray for osteoporosis. The company can get full FDA approval in June, when a 180-day exclusivity period expires for Apotex, another generic maker. MDRNA now focuses on developing RNA interference drugs, not nasal sprays. It is evaluating options on what to do with the osteoporosis drug.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
